HeroSupport is a Geneva University Hospital (HUG) spinoff developing medical devices that transform imaging and treatment tables into patient-specific supports so the table adapts to each patient. Its technology aims to make cancer treatment more precise and effective by improving patient comfort, reducing treatment duration and costs, and lowering side-effects through elimination of x-ray imaging. The company is led by founder and CEO Dr. Giovanna DiPasquale, a Medical Physicist at HUG. HeroSupport previously received a FIF Grant of CHF 50,000 in 2021 and has now been awarded further FIF funding to advance its technology. The recent award is a convertible FIF seed loan that will support continued development and scale-up within the FIF program. The product benefits and grant/loan awards position the company to progress clinical and commercial development in the near term. HeroSupport is a Geneva-based medtech startup that develops 3D-printed personalised patient-positioning immobilisation devices for prone breast radiotherapy. Its first product, VENUS SHELL, is an MRI-compatible custom breast shell created by 3D scanning the patient’s breast on the EYE-table and 3D printing a personalised shell that attaches to hospital treatment boards for precise, comfortable, and quick positioning. The company positions the device as improving treatment effectiveness, safety, and cost-efficiency and aims to increase use of prone positioning, which the article notes reduces skin burns and lowers lung and cardiac death risks. HeroSupport spun out of Geneva University Hospital, where the device was tested in a clinical trial, and was founded by CEO Giovanna Dipasquale and CTO Johan Uiterwijk. It received CHF 150,000 from Venture Kick and will use the funds to set up a 3D printing lab and complete certification to work with its first customers. The startup is currently raising its first financing round to accelerate international expansion and plans to target large radiotherapy centres in the EU, US, and Australia.

Total raised

$114M

Funding rounds

2

Latest round

Debt Financing

Latest activity

Feb 2024